Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

ANTA PHAR
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (USD)
Sales 2018 -
EBIT 2018 -37,2 M
Net income 2018 -31,1 M
Debt 2018 -
Yield 2018 -
Sales 2019 9,34 M
EBIT 2019 -33,1 M
Net income 2019 -32,9 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0,73x
Capitalization 6,86 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases.It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A... 
More about the company
Latest news on ANTA PHAR
06/18ANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
AQ
05/30ANTHERA PHARMACEUTICALS INC : Other Events (form 8-K)
AQ
05/23ANTHERA PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
AQ
05/15ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
04/17ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Costs Associated with ..
AQ
04/16ANTHERA PHARMACEUTICALS INC : Costs Associated with Exit or Disposal Activities,..
AQ
03/18ANTHERA PHARMACEUTICALS : Ends Development of Treatment for Cystic Fibrosis-rela..
AQ
03/16ANTHERA PHARMACEUTICALS : Reports Top Line Data from the RESULT Phase 3 Clinical..
AQ
03/14ANTHERA PHARMACEUTICALS : pulls the plug on Sollpura after Phase 3 failure, shar..
AQ
03/13HERE’S WHAT’S MOVING ANT : ANTH) and Advaxis, Inc. (NASDAQ:ADXS)
AQ
More news
Sector news : Bio Therapeutic Drugs
02:01pAlexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
More sector news : Bio Therapeutic Drugs
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,50 $
Spread / Average Target 1 997%
EPS Revisions
Managers
NameTitle
John Craig Thompson President, CEO & Executive Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
David E. Thompson Independent Director
Christopher S. Henney Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR7
GILEAD SCIENCES-1.97%91 317
VERTEX PHARMACEUTICALS3.44%39 504
REGENERON PHARMACEUTICALS-16.13%33 406
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
BLUEBIRD BIO INC-0.81%9 177